Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ith non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 According to the new ... Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) ... Trends to 2018", published by MarketsandMarkets, analyzes and studies ... as North America , ... the Rest of the World (RoW). Browse ...
(Date:7/29/2014)... Colo. , July 29, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... Times for taking a strong position in opposition ... Sunday, July 27, 2014 publication.  The New York ... and articles this week exploring the issue called ...
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... 2014 Quorum Review IRB, the ... awarded accreditation by the International Association of ... Six Sigma Deployment Program. The citation recognizes robust ... , Quorum’s Lean Six Sigma program was evaluated ... designation. The designation is a public statement of ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3
... Scientific ... Advisory Board --, SAN DIEGO, ... that it has received regulatory approval to,begin a Phase 2a proof-of-concept ... as metabolic arthritis, is a,painful and debilitating disease caused by abnormally ...
... (CellCyte) (OTC Bulletin Board: CCYG) has engaged InCap ... advice and,services. CellCyte seeks to build shareholder value ... work with InCap to initiate a corporate,partnering strategy ... and stem cell delivery technologies., "We are ...
... Organic-based devices, such as organic light-emitting diodes, require a ... it promotes injection of electron holes into an organic ... on July 8 at the International Conference on Science ... into factors that influence the injection efficiency. A balanced ...
Cached Biology Technology:Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4Research helps understand factors that influence efficiency of organic-based devices 2Research helps understand factors that influence efficiency of organic-based devices 3
(Date:7/29/2014)... of Maryland Schools of Dentistry (UM SOD) and ... have received a five-year $10.7 million grant award ... Diseases (NIAID) of the National Institutes of Health ... sexually-transmitted diseases (STDs). The grant, which renews a ... a new direction for the research by studying ...
(Date:7/29/2014)... that brings together two of the major disciplines behind ... insect fossils through stunning photographs and unique illustrations. , ... Jepson, details the incredible preservation and diversity of fossilised ... what these remarkable fossils can tell us about the ... our planet. Like the mosquito in Jurassic Park, many ...
(Date:7/28/2014)... A new discovery of two additional coral communities showing signs ... impact footprint of the 2010 spill in the Gulf of ... Charles Fisher, professor of biology at Penn State University. A ... on corals in the Gulf of Mexico will be published ... Early Edition of the journal Proceedings of the National ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... the southwestern United States are changing and will face ... declines during this century, according to a study conducted ... Service; University of California, Santa Barbara; U.S. Geological Survey; ... in the Proceedings of the National Academy of ...
... as any parent knows, colds and flu spread like wildfire, ... give a clearer picture of just how, exactly, infectious diseases ... can spread through a closed group of people, and even ... volunteers at a high school, Marcel Salath, a biologist at ...
... time ever, scientists have found a difference in the way males ... and that sexes likely use that difference to select their mates. ... a team of researchers who found that male and female cichlid ... ways as well. "It is difficult to say what ...
Cached Biology News:Drought and rising temperatures weaken southwest forests 2Human networking theory gives picture of infectious disease spread 2Human networking theory gives picture of infectious disease spread 3When it comes to selecting a mate, the eyes have it: Queen's University study 2
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... tubes - 96 x 0.3ml U-bottom ... - Thermo-Fast® 96 Non-Skirted Plate - ... x 0.5ml Thermo-Tubes Multiple workstations can be securely stacked ...
6B9...
Biology Products: